The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 31 of the 34 sources its claims cite were checked for support.
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Open accessAbstract
The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine is thought to produce rapid and sustained antidepressant effects through restoration of lost synaptic connections. We investigated this hypothesis in humans for the first time using positron emission tomography (PET) and [11 C]UCB-J-a radioligand that binds to the synaptic vesicle protein 2A (SV2A) and provides an index of axon terminal density. Overall, we did not find evidence of a measurable effect on SV2A density 24 h after a single administration of ketamine in non-human primates, healthy controls (HCs), or individuals with major depressive disorder (MDD) and/or posttraumatic stress disorder (PTSD), despite a robust reduction in symptoms. A post-hoc, exploratory analysis suggests that patients with lower SV2A density at baseline may exhibit increased SV2A density 24 h after ketamine. This increase in SV2A was associated with a reduction in depression severity, as well as an increase in dissociative symptoms. These initial findings suggest that a restoration of synaptic connections in patients with lower SV2A at baseline may underlie ketamine's therapeutic effects, however, this needs replication in a larger sample. Further work is needed to build on these initial findings and further establish the nuanced pre- and post-synaptic mechanisms underpinning ketamine's therapeutic effects.
Overview
CoChat Summary
TL;DR
This first-in-human study used [11C]UCB-J PET to test whether ketamine increases synaptic density (SV2A) in healthy controls and individuals with MDD and/or PTSD. It found no measurable overall SV2A change 24 hours after a single ketamine dose despite robust symptom reduction, but a post-hoc analysis suggested increases in those with lower baseline SV2A.
Key findings
- No significant change in SV2A density ([11C]UCB-J VT) 24 hours after ketamine in healthy controls (n=9; mean change 0.5%) or clinical participants (n=12; mean change 2.4%) across dlPFC, ACC, or hippocampus (all p>0.05); group-by-time effects were also non-significant.
- Ketamine produced robust antidepressant effects in the clinical group: MADRS reductions of -80±19% immediately, -66±24% at 24 hours, and -58±28% at 1 week (all p<0.001), alongside significant dissociative symptoms.
- In a post-hoc median split, the “SV2A deficit” clinical subgroup (n=6) had lower baseline SV2A density than age/sex-matched HCs (n=25) in dlPFC (p=0.005), ACC (p=0.001), and hippocampus (p<0.001); after ketamine, SV2A increased in dlPFC (8.7%, p=0.046, d=1.1), ACC (10.4%, p=0.035, d=1.2), and hippocampus (7.0%, p=0.054, d=1.0).
- In the “SV2A deficit” group, greater SV2A increase correlated with greater depressive symptom reduction in ACC (r=-0.91, p=0.011) and dlPFC (r=-0.818, p=0.047), and with derealization in ACC (r=0.817, p=0.047); non-human primates (n=4) showed no significant SV2A changes after ketamine or HNK at 24 hours, 1 week, or 4–6 weeks.
Methods
- Human participants: n=9 healthy controls and n=12 clinical participants (3 MDD, 5 MDD/PTSD, 4 PTSD) received intravenous racemic ketamine 0.5 mg/kg over 40 minutes and underwent [11C]UCB-J PET at baseline and 24 hours post-ketamine; primary ROIs were dlPFC, ACC, and hippocampus, with VT quantified using a 1-tissue compartment model and metabolite-corrected arterial input.
- Non-human primate study: four female rhesus macaques received ketamine 0.75 mg/kg IM or hydroxynorketamine (HNK) 1.5 or 3 mg/kg IM, with [11C]UCB-J PET at baseline and 24 hours, 1 week, and 4–6 weeks post-drug.
- Analyses used linear mixed-effects models for SV2A density and Pearson’s r for correlations with symptom change; clinical measures included MADRS, HAMD-17, BDI, PCL-5/PCL-S, and CADSS.
Limitations
- The paper states: the sample is small; the baseline-SV2A stratification analysis is post-hoc and exploratory and needs replication; clinical participants had mild-to-moderate symptom severity; a single ketamine dose may be insufficient; PET cannot distinguish synaptic density from vesicle number or SV2A expression; PET may be less sensitive than animal techniques; effects were highly variable; and change in free fraction (fP) correlated with change in VT in the “SV2A deficit” group.
- Evident from the text: the non-human primate sample was only n=4, and the post-hoc human subgroups contained only n=6 each, limiting statistical power and generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 Valid · 3 Not valid · 3 Not checked · 43 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The association between symptoms of derealization and antidepressant response is in line with the evidence base demonstrating a link between the dissociative and therapeutic effects of ketamine 58 .”
What the sources say
- Disputedcites [58] Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592–603. sourceExperimental — accuracy not yet measured
The Results report no statistically significant correlation between dissociative symptoms (CADSS scores) and depression outcomes (HAM-D-6 scores) at day 1 or day 3. The Discussion reiterates this finding, contrary to the claimed link between ketamine’s dissociative and therapeutic effects. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Importantly, we showed that only those MDD/ PTSD individuals with more severe depression exhibited lower SV2A density.”
What the sources say
- Supportedcites [22] Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1–10. source
The Results section (‘Group differences in synaptic density’; page not provided) reports significantly lower SV2A density in the high-depression-severity clinical group than in healthy controls, but no significant difference for the low-severity group. It also reports lower density in the high-severity group than in the low-severity group. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A wealth of preclinical research now points to the fundamental process underlying ketamine's antidepressant effects being an increase in synaptic connections 14 .”
What the sources say
- Supportedcites [14] Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49. source
In “Rapid acting antidepressants: mechanism of action” (page not supplied), the review reports that ketamine increases synaptic number and function and that persistent synaptic changes correlate with its antidepressant behavioral effects. It also describes preclinical mouse studies in which ketamine reverses stress-related neuronal and behavioral deficits, supporting the paraphrase. (LLM, conf=0.91)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Further, in the first study of its kind, we used positron emission tomography (PET) to provide the first direct in vivo evidence that lower synaptic density is associated with depression 22”
What the sources say
- Supportedcites [22] Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1–10. source
The Introduction explicitly calls this the first known in vivo evidence linking lower synaptic density with depression. The Results report lower PET-measured synaptic density in the MDD group and in participants with more severe depressive symptoms, supporting the attributed association. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This discovery fits with convergent evidence implicating a loss of synaptic connections in mood-related circuitry as a central pathophysiological process underlying depression and other stress-related disorders, such as PTSD 15,16 .”
What the sources say
- Partly supportedcites [15] Duman RS. Neurobiology of stress, depression, and rapid-acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31:291–6. sourceExperimental — accuracy not yet measured
The section “Stress and Depression Cause Loss of Synaptic Connections” (page unavailable) reports fewer synapses in depressed subjects and says synaptic loss could disrupt mood regulation. It also links PTSD to reduced volume in relevant brain regions, but does not establish synaptic loss as a central underlying process in PTSD; its proposed role in depression is qualified as a possibility. (LLM, conf=0.85)
- Partly supportedcites [16] Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, et al. Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep. 2017;19:74. sourceExperimental — accuracy not yet measured
In “Toward a Synaptic Deficit Hypothesis” (page unavailable), the paper says chronic stress reduces synapses in circuits regulating mood and that synaptic loss may be an important feature of PTSD neuropathology. It presents the PTSD link as a hypothesis supported by early clinical correlates, rather than establishing synaptic loss as a central underlying process; it also does not make that broader claim for depression and other stress-related disorders. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 5 with their cited sources checked
Create a free account to see all 67 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 14
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a recent study found that lower SV2A density at baseline in healthy volunteers and participants with MDD and/or PTSD predicted increases in SV2A density after ketamine administration”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [208]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“these increases, in turn, were associated with fewer depressive symptoms [208]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [208]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this increase in synaptic density was associated with a reduction in depression severity”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Use of synaptic vesicle PET ligands has recently revealed that ketamine produces similar synapsepromoting effects in the PFC in human depression [204].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [204]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Positron emission tomography (PET) with [11C]UCB-J, a radioligand targeting Synaptic Vesicle 2A (SV2A), has emerged as a minimally invasive translational tool to study disease- or drug-associated changes in synaptic density.10−12”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [10]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ References · p. 17
“Correlations were also significant in dlPFC and hippocampus.”
§ Post-hoc analysis based on baseline SV2A stratification · p. 7
“Correlations in the hippocampus were not significant (SV2A deficit: r=-0.678, p=0.139; no SV2A deficit: r=-0.329, p=0.589).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dissociative and antidepressant effects of ketamine · p. 6
“significant increases on the depersonalization, derealization and amnesia subscales of the ClinicianAdministered Dissociative State Scale (CADSS) in both HC and clinical groups”
§ Dissociative and antidepressant effects of ketamine · p. 6
“clinical group - depersonalization: p=0.003, d=1.12; derealization: p<0.001, d=1.33; amnesia: p=0.054, d=0.70”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ References · p. 19
“| Diagnosis | HC | HC | 3 MDD, 4 PTSD, 5 MDD/PTSD | 3 MDD, 4 PTSD, 5 MDD/PTSD |”
§ References · p. 20
“| Diagnosis | 3 MDD/PTSD, 3 PTSD | 3 MDD/PTSD, 3 PTSD | 4 MDD, 2 MDD/PTSD | 4 MDD, 2 MDD/PTSD |”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 2×
“The HAMD-17 [46], MADRS [47], and BDI [48] were used to assess participants’ mood at screening, at baseline scan, immediately after ketamine infusion, and 24 h after ketamine administration (as well as 1 week and 1 month post-ketamine for clinical participants).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 5×
“B MADRS scores at baseline, immediately, 24 h, and 1 week after ketamine administration in clinical subjects.”
MethodInfluentialPsychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696 · cited 2×
“The HAMD-17 [46], MADRS [47], and BDI [48] were used to assess participants’ mood at screening, at baseline scan, immediately after ketamine infusion, and 24 h after ketamine administration (as well as 1 week and 1 month post-ketamine for clinical participants).”
MethodMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“In a seminal study, the robust, rapid (within 4 h) and sustained (up to 1 week) antidepressant effects of an intravenous infusion of ketamine were observed for the first time [6].”
BackgroundSelf-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 1×
“Convergent evidence indicates that synaptic deficits observed in stress-related disorders may be precipitated by reduced neurotrophic and mTORC1 signaling [38, 39].”
BackgroundSelf-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 4×
“Given the doseresponse relationship between the glutamate surge, synaptogenesis, and antidepressant response following ketamine administration [28, 30, 54], it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
BackgroundInfluentialSelf-citationKaiser, R. H., Andrews-Hanna, J. R., Wager, T. D., & Pizzagalli, D. A. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0071 · Cited by 2,281
Research works printed but not linked: 1
- Kaufman MB. Pharmaceutical approval update. Pharm Ther. 2019;44:42–4.
Cited by
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“To date there has been a single pilot study directly addressing whether the antidepressant response to ketamine is associated with restoration of synapse density [132].”
BackgroundSelf-citationSynaptic plasticity and mental health: methods, challenges and opportunities
Appelbaum, L. G., Shenasa, M. A., Stolz, L., & Daskalakis, Z. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01370-w · Cited by 240
“Interestingly, despite significant symptom reduction, there was no associated change in SV2A density however, post-hoc analyses suggested that ketamine’s therapeutic effect may lie in restoring synapses in patients with lower baseline SV2A levels [38].”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“The authors also completed a post hoc study, showing that patients with lower SV2A density at baseline may exhibit an increased SV2A density 24 h after ketamine administration, coherent with the reduction in severity of depression (Holmes et al., 2022).”
BackgroundCanalization and plasticity in psychopathology
Carhart-Harris, R. L., Chandaria, S., Erritzøe, D., Gazzaley, A. H., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D., Rosas, F. E., Roseman, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109398 · Cited by 114
“Figuratively speaking, for the ‘internalizer’, belief-updating has ‘fallen into a rut’ (Holtzheimer and Mayberg, 2011); this person’s thinking and/or behavior has become entrenched in overly precise beliefs; they ‘go there’, likely because, given their experiences and circumstances (Maté, 2010),…”
BackgroundKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“…connectivity in participants, a recent study found that lower SV2A density at baseline in healthy volunteers and participants with MDD and/or PTSD predicted increases in SV2A density after ketamine administration; these increases, in turn, were associated with fewer depressive symptoms [208].”
Result
Metadata
- Authors
- Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., Duman, R. S., Sanacora, G., Krystal, J. H., Carson, R. E., & Esterlis, I.
- Affiliations
- Yale University (US)
- Corresponding author
- Holmes, Sophie E.
- Esterlis, Irina
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2022-02-15
- Volume
- 27
- Issue
- 4
- Pages
- 2273-2281
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9133063
- OpenAlex
- W4213048184
- Cited by
- 78
- References
- 67
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 23 · 2023: 15 · 2022: 8
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001863)
- Brain and Behavior Research Foundation (NA)
- Nancy Taylor Foundation for Chronic Diseases (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, synaptic density, SV2A, [11C]UCB-J, major depressive disorder, post-traumatic stress disorder, rapid-acting antidepressants, dissociative symptoms, depression severity
- MeSH terms
- Animals, Antidepressive Agents, Brain, Major Depressive Disorder, Humans, Ketamine, Macaca mulatta, Membrane Glycoproteins, Nerve Tissue Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. https://app.cochat.ai/papers/10.1038/s41380-022-01465-2
- The paper
- Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., Duman, R. S., Sanacora, G., Krystal, J. H., Carson, R. E., & Esterlis, I. (2022). Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01465-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.